Skip to main content

HCV

2
Pipeline Programs
8
Companies
26
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
2 DAAPhase 31 trial
Active Trials
NCT02247401Completed160Est. Aug 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
[14C]-PF-00868554Phase 11 trial
Active Trials
NCT00823745Completed7Est. Feb 2009
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
HCV, HBV, HIV testsN/A
HCV, HBV, HIV testsN/A
Alliance Pharmaceuticals
1 program
Community-based Simplified HCV Testing and Treatment AlgorithmN/A1 trial
Active Trials
NCT06604182Not Yet Recruiting1,454Est. Jul 2026
Kite Pharma
Kite PharmaCA - El Segundo
1 program
HCV, HBV, HIV testsN/A1 trial
Active Trials
NCT04286347Terminated363Est. Oct 2021
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium N/A
Genentech
GenentechCA - Oceanside
1 program
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium N/A1 trial
Active Trials
NCT02452814Completed8Est. May 2017
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
ProphylaxisN/A5 trials
Active Trials
NCT00000816Completed370Est. Sep 1996
NCT00000643Completed150Est. May 1994
NCT00000636Completed2,000Est. Oct 1997
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
AbbVie2 DAA
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Allergy TherapeuticsProphylaxis
Pfizer[14C]-PF-00868554
Allergy TherapeuticsProphylaxis

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 10,086 patients across 26 trials

NCT00000816Allergy TherapeuticsProphylaxis

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

Est. completion: Sep 1996370 patients
Phase 4Completed
NCT06738407Allergy TherapeuticsProphylaxis

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

Start: Jan 2026Est. completion: Jun 2028760 patients
Phase 4Not Yet Recruiting
NCT06908252Allergy TherapeuticsProphylaxis

MAPS PrEP Van Study

Start: Sep 2025Est. completion: Jul 202620 patients
Phase 4Recruiting
NCT03980223Allergy TherapeuticsProphylaxis

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

Start: Nov 2019Est. completion: Jun 2023641 patients
Phase 4Completed
NCT00001542Allergy TherapeuticsProphylaxis

Fluconazole Prophylaxis of Thrush in AIDS

Start: Jul 1996Est. completion: Nov 200180 patients
Phase 4Completed
NCT02247401AbbVie2 DAA

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Start: Nov 2014Est. completion: Aug 2016160 patients
Phase 3Completed
NCT00000643Allergy TherapeuticsProphylaxis

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

Est. completion: May 1994150 patients
Phase 2Completed
NCT02788227Allergy TherapeuticsProphylaxis

Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

Start: Oct 2016Est. completion: Jun 202599 patients
Phase 2Completed
NCT02213328Allergy TherapeuticsProphylaxis

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

Start: Apr 2015Est. completion: Mar 2017148 patients
Phase 2Completed
NCT02022657Allergy TherapeuticsProphylaxis

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Start: Apr 2014Est. completion: Jan 201752 patients
Phase 1/2Completed
NCT00000739Allergy TherapeuticsProphylaxis

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Est. completion: Jun 199896 patients
Phase 1Completed
NCT04760691Allergy TherapeuticsProphylaxis

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Start: Mar 2021Est. completion: Mar 202513 patients
Phase 1Completed
NCT04283461Allergy TherapeuticsProphylaxis

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Start: Mar 2020Est. completion: Apr 2022120 patients
Phase 1Completed
NCT00823745Pfizer[14C]-PF-00868554

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

Start: Jan 2009Est. completion: Feb 20097 patients
Phase 1Completed
NCT00000636Allergy TherapeuticsProphylaxis

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Est. completion: Oct 19972,000 patients
N/ACompleted
NCT00000959Allergy TherapeuticsProphylaxis

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

Est. completion: Jun 1996600 patients
N/ACompleted
NCT06604182Alliance PharmaceuticalsCommunity-based Simplified HCV Testing and Treatment Algorithm

Innovate, Involve, Inspire

Start: Jan 2025Est. completion: Jul 20261,454 patients
N/ANot Yet Recruiting
NCT05653232Allergy TherapeuticsProphylaxis

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Start: Apr 2023Est. completion: Mar 2027120 patients
N/ARecruiting
NCT04286347Kite PharmaHCV, HBV, HIV tests

HCV, HBV, HIV Testing During Consultation With Anesthesiologist

Start: Aug 2021Est. completion: Oct 2021363 patients
N/ATerminated
NCT04426656Allergy TherapeuticsProphylaxis

The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China

Start: Jul 2020Est. completion: Apr 202170 patients
N/ACompleted
NCT04330989Allergy TherapeuticsProphylaxis

An Integrated Strategy to Support Antiretroviral Therapy and Pre-exposure Prophylaxis Adherence for HIV Prevention in Pregnant and Breastfeeding Women

Start: Mar 2020Est. completion: Feb 2022300 patients
N/ACompleted
NCT02452814GenentechLong Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Start: May 2014Est. completion: May 20178 patients
N/ACompleted
NCT02094508Allergy TherapeuticsProphylaxis

Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda

Start: Mar 2014Est. completion: Dec 2016173 patients
N/ACompleted
NCT01808352Allergy TherapeuticsProphylaxis

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Start: Aug 2013Est. completion: Sep 2015226 patients
N/ACompleted
NCT01650558Allergy TherapeuticsProphylaxis

Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi

Start: Nov 2012Est. completion: Jul 20181,499 patients
N/ACompleted
NCT01632995Allergy TherapeuticsProphylaxis

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

Start: Oct 2012Est. completion: Feb 2015557 patients
N/ACompleted

Related Jobs

Clinical Program Manager, Medical Affairs Research Operations

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite - Hybrid Eligible)
1w ago
$182K - $236K/yr

Assoc. Spclst, Engineering

Verona PharmaVerona Pharma
IRL - Tipperary - Ballydine (Hybrid)
1w ago

Assoc. Spclst, Engineering

Merck & Co.Merck & Co.
IRL - Tipperary - Ballydine (Hybrid)
1w ago

Manager, Regulatory Operations

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite - Hybrid Eligible)
1w ago
$136K - $176K/yr

Senior Director, Medical Affairs Framework

Gilead SciencesGilead Sciences
United States - New Jersey - Parsippany (Onsite - Hybrid Eligible)
1w ago
$255K - $331K/yr

Director, Marketing- Digital Customer Experience

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite - Hybrid Eligible)
2w ago
$226K - $293K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 10,086 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.